Abionyx jumps as Stifel starts coverage with 'buy'
BUZZ-Abionyx jumps as Stifel starts coverage with 'buy' ** Shares of Abionyx ABNX.PA rise around 6% after Stifel initiates the French biotechnology firm with "buy" rating and €8.50 price target, implying nearly 400% upside to Wednesday's €1.70 closing price
** "Near-term orphan opportunity with multiblockbuster sepsis upside," the broker says about the company
** Abionyx's main drug candidate, CER-001, is being developed for sepsis, a potentially life-threatening response to infection, and LCAT deficiency, an extremely rare disease with no approved treatment
** Phase 2b sepsis trial is expected to begin in Q4, with initial data anticipated in H1 2028; an LCATA-deficiency marketing-authorisation filing is targeted for 2028
(Reporting by Nathan Vifflin in Gdansk)
((nathan.vifflin@thomsonreuters.com; gdansk.newsroom@thomsonreuters.com; +48 58 769 67 13;))
Recent news on Abionyx Pharma SA
See all newsBrief: ABIONYX Pharma And OLON Enter Into Strategic Manufacturing Partnership
France's ABIONYX Pharma H1 net loss widens as financial expenses rise
Brief: ABIONYX Pharma H1 EBIT EUR -2.27 Million
Abionyx jumps as Stifel starts coverage with 'buy'
Cardiovascular drug developer ABIONYX Pharma's H1 revenue falls